News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synthetic Blood International, Inc. (SYBD) Announces Plans to File Protocol for Phase II-b Oxycyte(R) Clinical Trial



4/4/2008 8:36:53 AM

COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that it intends to file a clinical protocol next week with the U.S. Food & Drug Administration (FDA) for its planned Phase II-b clinical trial of Oxycyte® in Traumatic Brain Injury (TBI) patients. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES